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Aim To estimate the hepatitis C virus (HCV) vertical trans-
mission rate, the effect of potential risk factors, and the pat-
tern of HCV antibody response and viremia in HCV-infect-
ed infants in Benha, Egypt.
Methods A total of 1224 pregnant women who were 
treated at Benha University Hospital, Egypt, were includ-
ed in the study. They completed a questionnaire about risk 
factors for HCV acquisition and suspected risk factors for 
mother-to-infant transmission and were tested for HCV an-
tibody using a third-generation ELISA test. Women positive 
for HCV antibody were tested for HCV RNA by polymerase 
chain reaction. Peripheral blood of infants of positive HCV-
RNA women was tested for HCV antibody and HCV-RNA at 
1 and after 6 months of age.
Results Out of 1224 pregnant women, 105 (8.6%; 95% 
confidence interval, 7.05-10.17) were positive for HCV anti-
body. Only 83 (6.8%; 5.39-7.21) were positive for HCV-RNA. 
HCV infection was associated with older age (1.16; 1.1-1.2, 
P = 0.001), blood transfusion (2.69; 1.2-6.0, P = 0.016), and 
HCV infection of the husband (5.47; 1.4-21, P = 0.014) or 
other household members (2.29; 1.2-4.6, P = 0.019). Out of 
53 infants tested at first month, 43 (81%; 71-92%) were pos-
itive for HCV antibody, but only 7 (13%; 4.1-22%) were posi-
tive for HCV-RNA. After 6 months, only 2 (3.8%; 0-8.95%) 
remained positive for HCV RNA.
Conclusions The prevalence of HCV in pregnant women 
in Egypt is lower than previously reported and the poten-
tial risk factors associated with HCV infection suggest in-
tra-familial transmission. The frequency of vertical trans-
mission of HCV in Egypt is not substantially different from 
other countries and does not play a role in the high preva-
lence of HCV in Egypt.
CLINICAL SCIENCES  
 
doi: 10.3325/cmj.2010.51.219
CLINICAL SCIENCE220 Croat Med J. 2010; 51: 219-28
www.cmj.hr
Worldwide, hepatitis C virus (HCV) infection is one of the 
most prevalent causes of liver diseases. There are estimat-
ed 300 million carriers of the virus all over the world (1). In 
the USA, the overall prevalence of HCV antibodies in the 
general population is 1.8%, the prevalence in children 6-11 
years is 0.2%, and in adolescents 12-19 years old is 0.4% (2). 
In most developed countries, HCV infection is associated 
with percutaneous blood exposure, primarily as a result of 
blood transfusion and intravenous drug addiction (3).
Egypt has the highest prevalence of hepatitis C in the 
world. Studies have found widely varying levels (10-50%) 
of the prevalence, depending on the populations covered; 
overall, estimates of the HCV rate in the general population 
range between 10 and 20% (4,5). Geographically, hepatitis 
C prevalence is higher in Lower Egypt (Nile delta) than Up-
per Egypt, and it is lower in urban than rural areas (6).
In Egypt, the use of contaminated needles and syringes 
during mass schistosomiasis treatment campaigns during 
the period the 1960s-1980s has been identified as a key 
mode of transmission for HCV infection, suggesting that 
parenteral exposure continues to cause infections (7). Evi-
dence of high interfamilial HCV transmission was found in 
a study in a rural community in the Nile Delta in the 1990s 
(5-8), although the exact modes of transmission were not 
identified.
Vertical transmission may help to explain the high prev-
alence in Egypt. This type of transmission in France is es-
timated to be less than 6% in HIV- negative patients (9). 
Indeed, a review of 13 studies on vertical transmission of 
HCV showed that the overall rate was 5.2% (10). However, 
a brief report from Egypt showed that vertical transmis-
sion of HCV was 36% (11), but this study looked at a small 
sample of 19 out of 100 pregnant women positive for HCV 
antibody, and only 14 of them were positive for HCV RNA. 
The sample of Kassem et al (11) comprised 100 randomly 
selected HIV-negative pregnant women and was too small 
for a valid estimation of the proportion of vertical transmis-
sion. It also used a limited definition of vertical transmis-
sion, defining it as the presence of HCV RNA in cord blood, 
and it did not repeat the polymerase chain reaction (PCR) 
test for HCV-RNA for infants after 6 months.
The aim of the present article was to perform a more ex-
tensive study to estimate the HCV vertical transmission 
rate, the effect of potential risk factors, and the pattern 
of HCV antibody response and viremia in HCV-infected 
infants in Benha, Egypt.
MetHodS
Site
The study was conducted in Benha, the capital of Qualy-
abia governorate, a small city 35 km north of Cairo. It is a 
semi-urban area with irrigated farmlands and surrounded 
by canals, a feature typical of the Nile delta. It has the char-
acteristics typical of a Lower Egyptian community: a mix-
ture of urban and rural areas, with significant influence of 
Egyptian traditions and attitudes. Benha University Hospi-
tal is one of the largest hospitals in Benha city. This hospital 
accepts patients from Benha city and the rural areas from 
Menufia and Sharkia governorates nearby (village house-
holds, inhabited mainly by farmers and their families). Most 
of the community studies on HCV in Nile delta have been 
conducted in Qualyabia and Menoufia.
Study design and population
This prospective study was conducted in two stages: the 
first stage was a cross-sectional study to identify the prev-
alence of HCV among pregnant women and the second 
stage was a longitudinal study of the infants of infected 
women to identify the rate of vertical transmission. The 
study population included all pregnant women who were 
admitted at the obstetric emergency department at Benha 
University Hospital (Benha, Egypt) for delivery between 
October 2003 and July 2008. The women who gave birth 
more than once during the study period were not includ-
ed in the study. We did not test for HIV, which is exceed-
ingly rare in rural Egyptian communities.
The study protocol was approved by the clinical research 
committee of Benha University Hospital, the Institutional 
Review Board of the Egyptian Ministry of Health and Pop-
ulation, and the National Hepatology and Tropical Medi-
cine Research Institute (Cairo). Patients were asked to sign 
a written consent for the study.
data collection
After signing the consent form, the authors conducted in-
terviews with the women using a standardized question-
naire designed by a team of sociologists, epidemiologists, 
and clinicians familiar with the risk factors for HCV acquisi-
tion and suspected risk factors for mother-to-infant trans-
mission of HCV (older age, history of blood transfusion, du-
ration of marriage, parity of more than two, husband and 
other household members positive for HCV). This ques-
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tionnaire assessed sociodemographic characteristics, pres-
ent and past health, and potential risk factors for exposure 
to HCV and mother-to-infant transmission of HCV. The ad-
dress and phone number of the patients and the name 
and phone number of close relatives were taken to facili-
tate follow-up and decrease patient loss during the study.
Specimen collection and serological testing of pregnant 
women. After the questionnaire was filled out, blood sam-
ples (10 mL) were taken from the pregnant women and 
sent to the laboratory. Serum alanine transaminase level 
(ALT) was assessed within 6 hours of sampling using ALT 
FLEXTM, AR model of the DIMENSIONTM system (Dade Beh-
ring Inc., Newark, DE, USA). When ALT was found to be el-
evated, additional tests were performed to exclude met-
abolic and viral liver disease other than hepatitis C. The 
serum was separated and aliquoted into 3 cryotubes, one 
aliquot was sent in an ice bag to the HCV Reference Labo-
ratory at the National Hepatology and Tropical Medicine 
Research Institute (Cairo), where the serum was tested for 
HCV antibodies using a third-generation ELISA test (Axsym 
System HCV, version 3.0, Abbott Diagnostics Division; Wi-
esbaden, Germany) as recommended by the manufactur-
er. The other two aliquots were stored in -70°C freezers to 
be tested later if needed. Infected pregnant women were 
identified by testing serum for the presence of HCV anti-
body. Serological samples that were positive for HCV an-
tibody were tested for the presence of HCV-RNA using a 
procedure of whole-serum amplification of DNA based on 
an in-house reverse transcription-nested polymerase chain 
reaction (RT-PCR). Pregnant women were considered in-
fected only if both the HCV antibody and HCV-RNA tests 
were positive.
Serological testing of infants and classification of results
Infected patients who tested positive were called back to 
get a peripheral blood sample from their infants. HCV an-
tibody testing was done first on the infants and then posi-
tive HCV antibody samples were tested for HCV-RNA. In-
fants were considered uninfected if they had never been 
positive for HCV RNA or if they cleared anti-HCV antibod-
ies after 6 months of age. Infants were considered to have 
perinatal mother-to-infant transmission if they were HCV-
RNA positive at any time following birth or showed anti-
HCV antibodies after 6 months of age. They were consid-
ered to have transient perinatal HCV infection if they were 
positive for HCV RNA at the 6-month visit, but negative for 
both anti-HCV and HCV-RNA after the 6-month visit. The 
children continuing to have HCV-RNA after the 6-month 
visit were considered to have persistent perinatal HCV in-
fections. Anti-HCV antibodies detected in the blood of 
children whose mothers tested positive for anti-HCV an-
tibodies 2-6 months after delivery were considered to be 
maternally acquired (12).
PCR-based detection of HCV-RNA
The protocol was based on a previously published proce-
dure (13) modified to increase the sensitivity of the assay. 
HCV RNA was detected by PCR (HCV AMPLICORTM, Roche 
Diagnostic systems, Inc., Branchburg, NJ, USA) and quan-
tified by the branched DNA signal amplification test (b-
DNA) (QuantiplexTM HCV RNA 2.0, Chiron diagnostics, Em-
eryville, CA, USA). Samples were prepared as a 3:10 dilution 
using 3 µL of serum and 7 µL of phosphate buffered saline 
in thin-walled PCR tubes. Tubes were incubated at 95°C for 
4 minutes and chilled on ice for 10 minutes, prior to the ad-
dition of RT-PCR master mix (Promega, Madison, WI, USA). 
RT-PCR reactions were carried out in a total volume of 100 
µL containing 1X Taq buffer with 1.5 mM MgCl2, 0.2 mM 
dNTPs (Promega), 20 pmol each of primer 1 (PSEA-HCV-
1, 5′ HEX- AAG GAC CCG GTC GTC CT 3’; Sigma-Genosys, 
Woodlands, TX, USA) and primer 2 (PSEA-HCV-2, 5’ FAM- 
TAT CCA AGA AAG GAC CCA 3’; Sigma-Genosys), 20 units 
of ribonuclease inhibitor (RNasin; Promega), 10 units of MV 
Reverse Transcriptase (RT; Promega), and 2.5 units of Taq 
DNA polymerase (Roche Diagnostic Systems). Master mix 
(90 µL) (Promega) was added to each sample and the mix-
ture was incubated at 42°C for 30 minutes and at 95°C for 
4 minutes followed immediately by 35 cycles at the follow-
ing conditions: 94°C for 1 minute, 50°C for 1 minute, 72°C 
for 1 minute, and a final cycle of 72°C for 10 minutes. The 
second PCR, using the inner primer 3 (PSEA-HCV-3, 5’ FAM- 
CAA CAC TAC TCG GCT AGT 3’; Sigma-Genosys) and primer 
4 (PSEA-HCV-4, 5’ HEX- CAT GGC GTT AGT ATG AGT GTT 3’; 
Sigma-Genosys), was performed by transferring 10 µL from 
the initial reaction to 90 µL of master mix (1X Taq buffer, 0.2 
mM dNTPs, 20 pmol of each nested primer, and 2.5 units of 
Taq polymerase). The samples were incubated for 35 cycles 
as in step 2 without the RT step. The PCR products were 
analyzed on 3% agarose in 0.5X TBE buffer.
The primers were derived from the highly conserved 5’-
untranslated region of the HCV genome to allow nested 
amplification of a 237-base pair product. Negative sam-
ples were retested for PCR after RNA extraction using the 
QIAamp Viral RNA kit (catalog No. 52906, Qiagen, Hilden, 
Germany). The sensitivity of the assay was 50 IU/mL ac-
cording to the manufacturer’s information. Despite 
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its greater sensitivity, an in-house nested RT-PCR invites 
problems with contamination and should be used with 
extreme care in the clinical setting.
Statistical analysis
The sample size for this study was calculated according 
to the primary aim (assess the prevalence of HCV among 
pregnant women). Demographic and laboratory data 
were compared for the infected pregnant women with 
non-infected group using χ2 and Fischer exact tests for 
categorical or dichotomous variables, and the unpaired 
independent t-test for continuous variables. Differences 
were considered significant for P values of 0.05 or less. 
Significant parameters were included in a multivariate lo-
gistic regression analysis to identify independent predic-
tors of HCV positivity among pregnant women, and the 
odds ratio was calculated for each significant parameter. 
Rate of vertical transmission was calculated based on the 
frequencies of HCV-RNA PCR positivity in mothers and 
their infants.
ReSultS
Design and follow up are shown in Figure 1. The study 
was carried out among 1224 pregnant women (mean age, 
25.3 ± 5.1 years; range, 16-45 years) who came for delivery to 
the obstetric emergency department at Benha University 
Hospital. Pregnant women with metabolic or viral diseases 
other than hepatitis C (114 women) and women who gave 
birth more than once during the study period (67 women) 
were not included in the study. Of 1224 pregnant women, 
105 (8.6%) were positive for HCV antibodies. Only 83 (6.8%) 
were positive for HCV-RNA by PCR, corresponding to 79% 
of women positive for HCV antibodies. Table 1 shows the 
results of univariate analysis of risk factors for HCV infec-
tion among pregnant women. There was an association 
between HCV infection and the following variables: old-
er age (P < 0.001), history of blood transfusion (P = 0.016), 
marriage lasting more than 3 years (P < 0.001), a former or 
current husband with HCV (P = 0.014), other household 
members infected with HCV (P = 0.019), and parity of more 
than two (P < 0.001). Although the proportion of HCV-posi-
Figure 1.
design and follow up of the study. Abbreviations: HCV – hepatitis C virus; PCR – polymerase chain reaction.
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tive women living in rural areas (72 of 83, 87%) was slightly 
higher than that of uninfected women (919 of 1141, 80%), 
this difference was not significant (P = 0.16).
Table 2 shows the results of multivariate analysis. Indepen-
dent risk factors for being positive for HCV-RNA by PCR 
were the following: older age (P = 0.001), history of blood 
transfusion (P = 0.016), a former or current husband infect-
ed with HCV (P = 0.014), and other household members 
positive for HCV (P = 0.019).
Out of the 83 infected mothers, samples of only 47 moth-
ers and 53 children (6 mothers delivered twins) were avail-
able. Of these 83 infected mothers, 3 (3.5%) mothers had 
still births, 27 (33%) were lost to follow-up, 6 (7%) withdrew 
consent, and 6 (7%) had twins. Out of the 53 infants tested 
in the first month of life, 43 (81%) were positive for HCV 
antibodies, and 10 (19%) were negative. The latter group 
was considered as non-infected infants without maternal-
ly-acquired antibodies. Of the 43 infants positive for HCV 
antibodies, only 7 (13%) were found positive for HCV-RNA 
by PCR; these were considered to be HCV-infected infants. 
HCV-RNA was not detected in 36 of 43 (87%) of infants 
born to HCV-RNA positive mothers; this group was con-
sidered as non-infected infants with maternally-acquired 
antibodies. At 6 months of age, 6 children who had been 
found positive for HCV-RNA by PCR were examined again; 
one mother withdrew consent for her children. Only two 
of the 53 (3.8%) remained positive for HCV-RNA; this pair 
was considered to show persistent HCV infection. The oth-
er 4 infants (7.6%) cleared their HCV-RNA and sero-revert-
ed to become negative for HCV antibodies; this group was 
considered to show clearance of perinatal HCV infection.
Patients lost to follow-up did not show significant demo-
graphic differences in comparison with patients who con-
tinued to participate. Loss of follow-up in infants who were 
tested during the first month was not high (14.2%).
dISCuSSIoN
Our study showed that the risk factors for HCV infection 
among pregnant women in an Egypt regions were older 
age, HCV-positive husband, administration of blood trans-
fusion, and HCV-positive other member of the house-
hold members. Egypt is considered one of the countries 
with the highest prevalence of HCV in the world (5), and 
a country with a high prevalence among children. There 
some reports claim that vertical transmission is higher in 
Egypt than in other countries (11), although these stud-
ies show some limitations in sample size and diagnostic 
method for determining vertical transmission. In the pres-
ent study, we aimed to assess the prevalence and risk fac-
tors of HCV among pregnant women in a small city in the 
Nile Delta, Egypt. We also sought to determine whether 
vertical transmission plays a major role in HCV endemic-
ity in Egypt.
Prevalence of HCV among pregnant women
We found the prevalence of pregnant women positive for 
HCV-RNA to be 6.8%. This study included women ranging 
in age from 16 to 45 years, with a mean age of 25.3. The 
prevalence in this age group was lower than reported in 
Egypt before: 37.5% among those older than 30 years, 
with a marked increase among those in their thirties and 
forties, and a peak of over 60% among those in their six-
ties (5). Our lower prevalence may be explained by 









(n = 83) P*
Age (years, mean±SD) 25.1 ± 4.8 29.5 ± 6.1 <0.001
Rural residency, No. (%) 919 (81) 72 (87)   0.16
Blood transfusion, No. (%) 45 (3.9) 12 (15) <0.001
Hospitalization, No. (%) 317 (28) 25 (30)   0.6
Major operation, No. (%) 319 (28) 24 (29)   0.9
Major accidents, No. (%) 9 (0.8) 1 (1.2)   0.7
Schistosomiasis history, No. (%) 22 (1.9) 3 (3.6)   0.3
Other household members who 
are HCV-positive, No. (%)
7 (0.6) 4 (4.8) <0.001
HCV positive husband, No. (%) 90 (7.9) 13(16)   0.01
Parity >2, No. (%) 290 (25) 41 (49) <0.001
Duration of marriage in years 
(mean±SD)
4.4 ± 4.4 7.4 ± 6.7 <0.001
Number of pregnancies, No. (%) 2 ± 1.3 3.3 ± 3.5 <0.001
Alanine transaminase (international 
units, mean±SD)
18 ± 19 21 ± 14   0.2
*Pearson χ2 test and Fisher exact test. Sd – standard deviation.
tAble 2. Multivariate logistic regression analysis for risk factors 
with HCV infection among pregnant women
Parameter
odds ratio 
(95% confidence interval) P
Age (years) 1.16 (1.1-1.2) 0.001
HCV-positive husband 5.47 (1.4-21) 0.014
Blood transfusion 2.69 (1.2- 6.0) 0.016
Other household members 
who are HCV positive
2.29 (1.2-4.6) 0.019
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a cohort phenomenon among patients treated by paren-
teral anti-schistosoma therapy (PAT) in Egypt from 1960s-
1980s. Our study group contained a smaller proportion of 
PAT-treated cohort than did the studies conducted more 
than 10 years ago, which may explain the lower prevalence 
of HCV.
Our study also found a slightly higher rate of infection 
among women living in rural areas than in urban areas, 
though this difference was not significant. As reported by 
Frank et al (7), higher infection rates among older wom-
en and rural residents may be partially explained by the 
differential exposure of these groups to schistosomiasis 
campaigns in Egypt, and the use of contaminated needles 
or syringes during treatment campaigns, suggesting that 
parenteral exposure continues to be a major transmission 
route for HCV infection in Egypt (7).
Evidence suggests that our data indeed reflect a decrease 
in HCV prevalence. Our patients came from the same areas 
as in the studies reporting higher prevalence of HCV (5). 
In addition, other studies published recently have shown 
a decrease in HCV prevalence in Egypt (14). Although the 
prevalence of HCV in Egypt appears to have decreased, our 
prevalence of 6.8% is still higher than in other countries 
such as the USA (3.2%), Taiwan (1.5%), Zaire (6%), and Saudi 
Arabia (0.6%) (2,15,16). Risk factors for this high prevalence 
should be studied, especially the avoidable ones.
Risk factors for HCV infection
Although in this study there were many factors associated 
with HCV infection in univariate analysis, multivariate anal-
ysis found only 4 independent risk factors. Old age was the 
first independent factor, which suggests the same cohort 
phenomenon described above and the cumulative effect 
of exposure to HCV due to the long period of viral exposure 
over one’s lifetime, as well as exposure to other potential 
HCV risk factors. Our results are in agreement with Costa 
et al (17), who indicated that HCV is associated with older 
age and not associated with ethnicity or greater number 
of pregnancies. Also, a previous community-based study 
in Egypt has found that older age patients have a higher 
prevalence of HCV (5,18).
Further independent risk factors were having a husband 
or another household member positive for HCV. This as-
sociation suggests that the significance of intrafamilial 
transmission of HCV is comparable with that of sexual 
transmission. Intra-familial transmission of HCV has also 
been reported by Mohamed et al (8).
Another risk factor was blood transfusion. Several pa-
tients in our group had received blood transfusions be-
fore blood donors in Egypt underwent routine screen-
ing for HCV. These patients also had other risk factors, like 
hospitalization and major operations. Although blood 
transfusion is now considered a less important risk factor, 
it should be considered carefully, especially in a country 
with such a high prevalence of the disease. Our results 
are in agreement with those of Sangha et al (19), who 
found that a history of surgery, blood transfusion, or in-
jection to treat schistosomiasis increased the risk of ac-
tive infection with hepatitis C, independent of the other 
characteristics.
We did not test for other hepatitis viruses or for HIV, which 
is exceedingly rare in rural Egyptian communities. A UN-
AIDS/WHO report from 2008 (20) estimated that HIV/AIDS 
was present in 9000 Egyptians, predominately men with 
high risk behaviors, who account for less than 0.1% of the 
total population. No HIV-positive pregnant women were 
reported during sentinel site surveillance outside of ‘‘major 
urban areas’’ from 1992 to 1996 and in 2004.
Mother-to-infant transmission for HCV
We found that only 13% of the 43 infants who were posi-
tive for HCV antibodies in the first month of life were also 
positive for HCV-RNA. We considered this group as HCV-
infected infants. This result is compatible with previous 
studies, which have found that most infants born to HCV-
positive mothers have HCV antibodies in their blood and 
that we cannot use the presence of these antibodies to 
diagnose vertical transmission until after 18 months (21). 
Although 43 of 53 (81%) infants had HCV antibodies in the 
first month of life, only 7 (13%) were positive for HCV-RNA 
at the same time. At 6 months of life, only 2 (3.8%) were 
positive for HCV-RNA, indicating persistent HCV infection, 
while the other 4 infants had cleared their HCV-RNA indi-
cating clearance of perinatal HCV infection. A similar fig-
ure for vertical transmission of HCV (4.6%) was reported 
recently from Egypt at one year of age (12). These results 
show that a large proportion of infants were only tempo-
rarily positive for HCV-RNA during the first weeks of life 
and the PCR test should be repeated again at 6 months 
of life. Studies that do not test infants when they are old-
er may lead to overestimates of HCV prevalence and this 
may be the case with community-based study of perina-
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tal HCV transmission in 3 rural Egyptian villages, where 
the overall HCV prevalence of more than 20% was found 
(5,22-24).
Frequent clearances of perinatal HCV infection may ex-
plain the previous reports of a high incidence of vertical 
transmission in Egypt. These reports have relied on cord 
blood samples or PCR results taken only once within a few 
weeks after delivery (11). Together with previous studies, 
the present study confirms that the incidence of vertical 
transmission of HCV in Egypt is similar to that in other parts 
of the world, where it varies from 4.5% to 6.0% (10,25-27), 
and that vertical transmission does not play a major role in 
the high endemicity of HCV in Egypt.
Our definition of perinatal transmission of HCV was that in-
fants had to be positive for both anti-HCV antibodies and 
HCV RNA. HCV-RNA was not detected in 36 of 43 (87%) 
of infants born to HCV-RNA positive mothers; this group 
was considered as non-infected infants with maternally-
acquired antibodies. Only 2 of the 53 infants (3.8%) re-
mained positive for HCV-RNA; this pair was considered to 
show persistent HCV infection. The other 4 infants (7.6%) 
cleared their HCV-RNA and sero-reverted to become 
negative for HCV antibodies; this group was considered 
to show clearance of perinatal HCV infection. Consistent 
with our approach, the European Pediatric HCV Network 
(EPHN) criterion for perinatal transmission of HCV in their 
multicenter trial of 1787 mother-child pairs was two or 
more positive HCV-RNA PCR test results and/or anti-HCV 
antibody positivity after 18 months of age (28,29). The 
EPHN trial did not include a transient infection category. 
Their study focused on risk factors for infection and did 
not show data about HCV-RNA positive children who did 
not meet their criteria for infection. However, they did de-
scribe 279 (16%) children classified as having “indetermi-
nate infection status,’’ who did not meet their criteria for 
either infected or none infected, and they classified the 
infants with fewer than two positive HCV-RNA results as 
non-infected (28). Members of the EPHN group subse-
quently reported on accuracy of HCV-RNA PCR testing for 
the diagnosis of vertically acquired HCV infections (30). 
Since they used the presence of anti-HCV at 18 months 
as their “gold standard’’ for mother-to-infant transmission, 
it is not surprising that they concluded the test was not 
reliable during the first few months of life. Sensitivity and 
positive predictive value of the PCR testing was poor, 
since children who had positive tests for HCV-RNA with-
out persistence of HCV antibodies and RNA were consid-
ered to be false positives.
We suggest that a higher proportion of infants born to 
HCV-infected mothers have infections and then clear 
their infections than is generally reported. In our study, 
this proportion was 13.2% in infants whose mothers were 
HCV-RNA positive, but it may have been greater if we had 
sampled the infants earlier and more frequently. When 
Ketzinel-Gilad et al (31) did this, they detected transient 
HCV-RNA in 5 of 23 (22%) infants born to 22 HCV-infected 
women. Ceci et al (31) conducted a 2-year follow-up of 
60 HCV-infected infants born to HCV-RNA-positive moth-
ers and reported that 75% cleared their infections. Ruiz-
Extremera et al (32) reported that 7 of 8 Spanish infants 
born to anti-HCV-positive mothers followed for an aver-
age of 29 months had detectable HCV-RNA and anti-HCV, 
both of which cleared. Others reported that 2 of 3 infants 
with perinatal HCV cleared their viremia by 2 months of 
age (33).
It is unlikely that the clearance observed in our study is 
due to cross-contamination or laboratory error leading to 
false-positive RT-PCR testing for RT-PCR results for HCV-
RNA. Firstly, mothers were tested during the last trimester 
of pregnancy; in contrast, children were tested after they 
were born; thus, the samples were not processed in paral-
lel, reducing the chance of cross-contamination. In addi-
tion, in most cases there was more than one positive blood 
sample; thus, anti-HCV antibody tests were performed in 
duplicate on most mothers and children. Lastly, none of 
the 1119 children born to mothers who did not have HCV 
antibodies had HCV infections.
Our study detected transient infections in 2 (9%) of 22 chil-
dren whose mothers had HCV antibodies in the absence 
of RNA. Although most studies have reported transmission 
of HCV to infants only from mothers who had detectable 
HCV-RNA (31,34-37), a large multicenter study has report-
ed 5 infections in infants from mothers who had only HCV 
antibodies (38). This may be due to fluctuating viremia that 
is undetectable at the time of testing.
For this reason, we used used the persistence of HCV anti-
bodies for more than 18-24 months in the absence of de-
tectable HCV-RNA as criterion for mother-to-infant trans-
mission of HCV (37,39-41). Gibb et al (40) has reported that 
among infants born to 441 HCV-infected mothers, half of 
uninfected infants cleared their anti-HCV antibodies by 8 
months and 95% were negative for anti-HCV antibodies 
at 13 months. Others have reported that anti-HCV an-
tibodies transmitted passively, disappeared in infants 
by 6 or 8 months (42-44), and 4 cases who were in-
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fected perinatally lost anti-HCV antibodies transferred pas-
sively from their mothers by 6-12 months before making 
their own anti-HCV antibodies (37). All these results sug-
gest some infants with anti-HCV antibodies persisting lon-
ger than 12 months could be infected cases with tempo-
rarily undetectable viremia.
Our 4 transiently infected infants cleared their HCV-RNA 
and sero-reverted to become negative for HCV antibod-
ies; this group was considered to show clearance of peri-
natal HCV infection. Others have reported that infants 
cleared their viruses without having persistent antibod-
ies (33,42,43), which could have several explanations. One 
of these could be the passage of neutralizing antibodies 
along with low titers of viral particles from mothers to 
their newborns; these antibodies could clear the infection 
and either abort or diminish the child’s antibody produc-
tion (45).
The fact that children are more likely to clear HCV infec-
tions than adults is supported by the finding that only 8 
of 33 children sampled in years 2 and/or 3 continued to 
be HCV-RNA positive (32). The 76% (25 of 33) HCV clear-
ance rate was much greater than the 23% clearance rate 
among the children in the EPHN multicenter project (29). 
However, these authors had different criteria for classify-
ing initial infection and only considered the clearance oc-
curring in children who remained infected until their first 
birthday. Using their criteria, about half the children in this 
report with HCV-RNA cleared their infections by their third 
birthday.
Potential limitations of this study need to be mentioned. 
Although the prevalence of HCV was assessed in a large 
number of pregnant women, it cannot exactly apply to the 
general population of Egypt because the selected sam-
ple consisted solely of women of childbearing age from 
only one area of Egypt. However, Roberts and Yeung (21) 
reviewed 12 studies from different countries that includ-
ed more than 3000 pregnant women and concluded that 
prevalence of HCV among pregnant women was not dif-
ferent from that of the age-matched general population 
(21). In addition, our results are consistent with those from 
previously published studies on the prevalence of HCV in 
Egypt from the same area that we studied; therefore, we 
believe that our results reliably indicate a change in the 
prevalence of HCV in Egypt. The sample size is inadequate 
for statistically identifying some potential risk factors for 
infant infection. The study was unable to show that 
most maternal or infant characteristics, including the 
infant’s sex and source of nutrition, were a risk for infection. 
The effect of breast-feeding upon the infants’ infection sta-
tus has been unclear and variable (28,31,34,38,41), so fur-
ther study is needed to address this. The second shortcom-
ing is the high dropout rate and loss to follow-up in our 
groups, despite the precautions that we took to avoid the 
loss of patients. Patients who were lost to follow-up were 
not different from patients who continued to participate in 
the study regarding demographic features. Loss to follow-
up in infants who were tested at the first month was not 
high (14.2%). The third shortcoming is that the relatively 
small sample size made the confidence interval of the es-
timated incidence of vertical transmission relatively wide. 
The short follow-up of our patients of merely 6 months is 
unsatisfactory; during the first year or two of life, serum 
HCV RNA may become positive, fluctuate between positive 
and negative, and in some cases seropositive cases can ex-
hibit spontaneous clearance. Because serum HCV RNA lev-
els fluctuate over time and longitudinal data have clearly 
shown that a baby initially negative for HCV-RNA may sub-
sequently test positive, the 43 babies initially negative for 
HCV-RNA should have been retested – for HCV-RNA at 6 
months and for anti-HCV antibodies at 12-18 months.
In conclusion, the prevalence of HCV in Egypt is lower than 
previously reported. Risk factors for vertical transmission 
suggest that intra-familial transmission is an important 
concern, and further studies are needed to explore this 
issue further. Incidence of vertical transmission of HCV in 
Egypt is not different than in other countries and it plays 
no role in the high endemicity in Egypt.
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